KPV vs BPC-157
Side-by-side comparison of KPV, BPC-157 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | KPV KPV (Lys-Pro-Val) — Alpha-MSH Tripeptide Recovery | BPC-157 Body Protection Compound-157 Recovery |
|---|---|---|
| Basics | ||
| Molecular type | Alpha-MSH C-terminal Tripeptide | Gastric Pentadecapeptide |
| Amino acids | 3 | 15 |
| Molecular weight | 355.4 Da | 1,419.5 Da |
| Half-life | Short (hours) | ~4 hrs (SC) |
| Route(s) | Subcutaneous, Oral (GI conditions), Topical | Subcutaneous, Intramuscular, Oral (research only) |
| Mechanism & Research | ||
| Primary mechanism | KPV binds melanocortin receptors (MC1R and MC3R) expressed on immune cells, epithelial cells, and neurons. Receptor activation suppresses NF-κB-mediated pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) and drives… | BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery o… |
| Research status | Research Compound | Research Compound |
| Evidence summary | KPV has robust preclinical data for inflammatory bowel conditions (Crohn's disease, ulcerative colitis models) and wound healing. Oral nanoparticle formulations have been developed to improve colonic delivery. | The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and e… |
| Protocol & Dosing | ||
| Typical dose | 500 mcg–2 mg/day (SC); variable oral dosing | 200–500 mcg per injection |
| Frequency | Once or twice daily | Once or twice daily |
| Duration | 4–8 weeks | 4–12 weeks |
| Timing | Any time; pre-meals for GI applications | Near injury site when possible |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Prohibited (WADA S0) |
| Deeper reading | ||
| Related peptides | BPC-157, LL-37, TB-500 | TB-500, GHK-Cu, KPV, Pentadeca Arginate |
| Full profile | Read full KPV profile → | Read full BPC-157 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.